logo
The maker of Taser is the highest paid CEO, taking home $165 million—his new pay package and soaring stock made him a billionaire last year

The maker of Taser is the highest paid CEO, taking home $165 million—his new pay package and soaring stock made him a billionaire last year

Yahoo2 days ago

Axon CEO Rick Smith topped the highest-paid CEOs list, reportedly raking in $165 million through stock incentives at his company, selling Tasers, security cameras, drones, and VR training. Smith became a billionaire last year due to his compensation package, boasting a net worth of $2.5 billion. But the tragic backstory behind his $17 billion company, which has driven its business ethos, may be partly false.
When imagining the highest paid CEOs, one might guess Jensen Huang leading Nvidia's breakout success, or Elon Musk helming his multiple tech successes. But the top executive taking home the bacon is the boss of Tasers.
Rick Smith, the co-founder and chief executive of Axon Enterprise, was the highest-paid CEO in 2024, a new report has revealed.
According to the WSJ, the Axon CEO got a $165 million pay package last year—topping that of Larry Culp's $89 million, Stephen Schwartzman's $84 million, and Tim Cook's $75 million. Smith's total pay is a 999% increase from his compensation in 2023, which has shot up dramatically since Axon's compensation revamp last year.
The Axon leader has run the company since 1993, and became a billionaire last year after the company changed its CEO wage strategy. Smith said he was inspired to launch the company—which manufactures Tasers, and has expanded to security cameras, drones, and VR training largely for government agencies—after two of his high school friends were gunned down. He saw Taser devices as a less lethal way to help end gun violence. But family members of the victims have rejected his claims.
While Smith tops this year's list of highest-paid CEOs, he made headlines last year for rising to billionaire status with a highly lucrative pay strategy.
Last year, Axon modeled its chief executive's total compensation after Musk's package at Tesla. Nearly all of his money lies in stock awards—which have been soaring over the past few years. Axon's revenue had grown more than 30% for three years straight by 2024, reeling in a record-breaking annual net income of $377 million. The business's shares also more than doubled in 2023, skyrocketing by over 50%. Combined with the rest of his pay package, he finally made the Bloomberg Billionaires index in 2024, boasting a net worth of $2.5 billion.
This type of compensation is high-risk, but also high-reward—if Axon doesn't meet its stock price, operations targets, and minimum service requirements for the years from 2024 to 2030, Smith doesn't receive his full pay package.
An Axon spokesperson told Fortune that the $165 million pay package 'does not represent realized pay, but rather the potential value of the award if all performance milestones are fully achieved over the life of the program.' The WSJ reported that two of Axon's seven performance targets had been met by March, according to the company's filings.
The Journal's analysis used data from MyLogIQ, a provider of public-company data, and included CEOs on the job for at least a year at more than 400 S&P 500 companies reporting pay through mid-May for fiscal years ending after June 30, 2024
However, one thing is clear: Smith's net worth has been ballooning as the company has grown. In 2019, he had a reported pay of $246 million catapulted by growing stocks. And over the past year, Axon's stock price rose 160%, pushing its market cap to $50 billion, and making the shares underlying Smith's rewards worth around $500 million.
The main ethos of the $17 billion company is to save lives—Smith espouses Taser devices as a less lethal alternative to guns. He has repeatedly said he got the inspiration to found the company after two of his high school friends on his football team were shot and killed. But the validity of his tragic backstory has been called into question.
Smith has long pushed this narrative, telling the story to crowds of law-enforcement officers; citing it in a filing with the U.S. Securities and Exchange Commission in 2020; and running it in company campaigns—including one celebrating Axon's 30th anniversary. But an investigation from Reuters has found many of Smith's claims appear to be false. It reported that Smith was not close friends with the deceased, and cited incorrect details about the incident. Axon spokesperson Alex Engel told Reuters that Smith got to know the slain young men through 'team-related social events.'
One of the victim's fathers has accused Axon of running 'a whole advertising campaign based on the murder of [his] son.' The victim's sister also said Smith was 'making money off of being a great liar.'
Whether or not the CEO was close friends with the shooting victims, a spokesperson from the company told Fortune it stands by his account that the tragic event inspired 'him to dedicate his life to reducing violence through technology.'
'We're proud of the mission-driven culture at Axon and remain focused on the work ahead,' a spokesperson said while taking aim at Reuters' reporting, which they described as a'five-year crusade to falsely defame our company.'
This story was originally featured on Fortune.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

Yahoo

time26 minutes ago

  • Yahoo

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

Exact Sciences Corporation's EXAS efforts to further promote its flagship Cologuard as the standard of care are encouraging. The company plans to transform cancer care by providing patients with valuable insights at every step of their diagnosis and treatment. Additionally, it continues to invest in a pipeline of innovative solutions for every stage of cancer diagnosis. However, unfavorable solvency and mounting costs from macroeconomic pressures raise concerns for EXAS' operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 23.5% against the 17.1% fall of the industry and the S&P 500 Composite's gain of 11.3%. The globally renowned medical device company boasts a market capitalization of $10.34 billion. It has a long-term earnings growth rate of 29.3% compared with the industry's 21.4%. Additionally, the company's earnings surpassed estimates in three of the trailing four quarters and fell short in another, delivering an average surprise of 48.8%. Strategic Priority Bodes Well: Exact Sciences is pushing Cologuard as the CRC screening benchmark, backed by 16 million test uses over the past decade. In the first quarter of 2025, screening revenues increased 14%, led by broad-based Cologuard growth. Continued success in rescreens, care gap programs and growth in new ordering providers fuels this momentum. Exact Sciences is investing in the leadership team, training and sales force efficiency, as well as simplifying the electronic ordering process to further drive growth. Rescreening patients every three years from age 45 is also expected to contribute. Image Source: Zacks Investment Research Meanwhile, the robust international adoption of Oncotype DX led to 4% year-over-year growth in Precision Oncology revenues. The test, included in all major breast cancer treatment guidelines, helps early-stage breast cancer patients by evaluating the need for chemotherapy and recurrence risk. With about 70% of the eligible patients outside the United States not currently being tested, there still remains a substantial opportunity to grow. Enhancing Customer Experience: The company is currently working to build the best digital infrastructure and diagnostics. This vision has two main elements: first, enabling patients to take a more proactive role in their care. Second, it makes it easy for physicians to order tests, interpret results and personalize medicine by applying real-world evidence and guideline recommendations. The combined strength of Exact Nexus, the company's proprietary technology platform, and EXAS' commercial capabilities is leading to more patients completing Cologuard every three years, supporting the company's goal of making screening a routine practice and also closing the screening gap. The company has identified more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through large, organized screening programs. Advancing New Solutions: In late March 2025, the company launched Cologuard Plus, the most accurate non-invasive CRC screening test reported in studies so far. The test rapidly secured Medicare coverage, pricing and quality measure guideline inclusion. With its enhanced specificity, Cologuard Plus is expected to reduce unnecessary follow-up colonoscopies by up to 40% compared to the original Cologuard test. Subsequent to the quarter's end, Exact Sciences marked another highly anticipated launch with its Oncodetect MRD test. Introduced as a laboratory-developed test (LDT), the company expects to obtain Medicare reimbursement through the Molecular Diagnostic Services Program in the second quarter of 2025. Furthermore, the Cancerguard MCED test is on track to be launched as an LDT later this year. The company is also making headway with its blood-based colon cancer screening test, with top-line results from the pivotal BLUE-C study expected by mid-2025. Strong Solvency but Highly Leveraged: Exact Sciences exited the first quarter of 2025 with cash and cash equivalents and marketable securities of $786 million and zero current debt. However, the company's significant indebtedness is a concern. Long-term debt of $2.32 billion was almost consistent with the fourth-quarter levels. Escalating Costs: Exact Sciences' business has been affected by global macroeconomic conditions. Disruptions in the United States, Europe or other economies, whether from geopolitical tensions or changing international trade policies, could disrupt global markets, interrupt global supply chains and lead to inflationary or recessionary effects on the worldwide economy. In addition, the high-interest rate environment and limited access to capital markets could strain the company's suppliers, distributors and key business partners, making it difficult for them to remain in business. All these are creating significant pressure on its profitability as well. In the past 30 days, the Zacks Consensus Estimate for Exact Sciences' loss for 2025 went from 61 cents to 14 cents in the past 60 days. The Zacks Consensus Estimate for the company's 2025 revenues suggests a 12.4% year-over-year improvement to $3.10 billion. Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. Phibro Animal Health has an estimated long-term earnings growth rate of 26% compared with the industry's 15.7%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 37.7% compared with the industry's 10.7% growth in the past year. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Hims & Hers Health, currently carrying a Zacks Rank #2, has an earnings yield of 1.3% against the industry's 11.9% yield. Shares of the company have surged 151.7% compared with the industry's 32.5% gain. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched on one occasion and missed on another, the average surprise being 2.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 4.1%. Shares of the company have rallied 25.8% against the industry's 22.4% fall. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Citadel CEO worried by rising cost of US default insurance
Citadel CEO worried by rising cost of US default insurance

Yahoo

time26 minutes ago

  • Yahoo

Citadel CEO worried by rising cost of US default insurance

By Carolina Mandl and Davide Barbuscia NEW YORK (Reuters) -Citadel's founder and CEO Ken Griffin said on Thursday it is "unfathomable" that a financial instrument to protect against an eventual U.S. default is being priced at levels close to some European countries. "I never thought in my life I would see the U.S. priced higher in risk cost than a number of countries like Spain, Germany or France," he said at the Forbes Iconoclast Summit. "You gotta be kidding me." Griffin said the credit default swap (CDS) market has some issues with liquidity which impact prices, but still he considered that conversations around how close the swaps are trading are "unfathomable." Spreads on U.S. five-year CDS - market-based gauges of the risk of a sovereign default – stood at 48 basis points on Thursday, compared to 50 bps for Italy, 32 bps for Spain and 35 bps for France, S&P Global Market Intelligence data showed. U.S. sovereign CDS spreads widened to their highest since the debt ceiling crisis of 2023 in recent weeks. The move in the spreads of U.S. credit default swaps comes amid concerns around the country's fiscal deficit and negotiations over a tax bill that is estimated to add more than $2 trillion to the U.S. debt. Griffin did not specifically comment on the bill, but criticized the U.S. fiscal deficit. "The United States' fiscal house is not in order. You cannot run deficits of six or 7% at full employment after years of growth. That's just fiscally irresponsible," he said.

Supreme Court rejects Mexico lawsuit against US gunmakers
Supreme Court rejects Mexico lawsuit against US gunmakers

Yahoo

time30 minutes ago

  • Yahoo

Supreme Court rejects Mexico lawsuit against US gunmakers

The US Supreme Court has blocked a lawsuit brought by Mexico that sought to hold American gunmakers accountable for playing a role in country's struggle with drug cartels. The court voted 9-0 to reject the suit, in the process upholding a 2005 law that shields gun manufacturers from liability if weapons they produce are misused. Mexico's government had argued that the "flood" of illegal guns across the border is a result of "deliberate" practices by US firms that they say appealed to cartel members with their products. The decision overturns a lower court's ruling that allowed the suit, brought against Smith & Wesson as well as other manufacturers, to proceed. The case is the first time the court has taken up the shield law, known as the Protection of Lawful Commerce in Arms Act, or PLCAA. At a hearing in March, the court appeared sceptical of Mexico's challenge, with justices on both sides of the ideological spectrum questioning the validity of the suit. Supreme Court wary of Mexico's fight against US gunmakers

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store